Compare BGSF & SCYX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | BGSF | SCYX |
|---|---|---|
| Founded | 2007 | 1999 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Professional Services | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 56.6M | 60.4M |
| IPO Year | 2013 | 2014 |
| Metric | BGSF | SCYX |
|---|---|---|
| Price | $5.05 | $4.30 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 1 |
| Target Price | N/A | ★ $3.00 |
| AVG Volume (30 Days) | 8.4K | ★ 288.0K |
| Earning Date | 05-06-2026 | 05-06-2026 |
| Dividend Yield | ★ 36.04% | N/A |
| EPS Growth | N/A | ★ 61.36 |
| EPS | N/A | ★ N/A |
| Revenue | ★ $93,310,000.00 | $257,000.00 |
| Revenue This Year | $4.67 | N/A |
| Revenue Next Year | N/A | $608.78 |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $3.26 | $0.57 |
| 52 Week High | $8.20 | $5.62 |
| Indicator | BGSF | SCYX |
|---|---|---|
| Relative Strength Index (RSI) | 42.65 | 71.37 |
| Support Level | $4.97 | $0.67 |
| Resistance Level | $5.36 | $5.62 |
| Average True Range (ATR) | 0.18 | 0.30 |
| MACD | 0.02 | 0.13 |
| Stochastic Oscillator | 43.18 | 72.56 |
BGSF Inc is a national provider of consulting, managed services, and professional workforce solutions. The company operates in one segment of Property Management, which includes centralized support services through executive, marketing, human resources, information technology, accounting, treasury, and billing operations.
SCYNEXIS Inc is a drug development company that focuses on the development and commercialization of novel anti-infectives to address unmet therapeutic needs. It is engaged in developing a product candidate, ibrexafungerp which is a novel oral and intravenous (IV) drug for the treatment of several fungal infections, including serious and life-threatening invasive fungal infections. The ibrexafungerp is a novel and structurally distinct triterpenoid glucan synthase inhibitor that is effective in vitro and in vivo against broad range of Candida and Aspergillus species, including drug-resistant strains as well as Pneumocystis, Coccidioides, Histoplasma and Blastomyces genera and some common mucorales species.